Is Kisspeptin-10 legal in New York?
status · caveats apply
Endogenous neuropeptide in Imperial College London Phase 1/2 trials; PCAC voted NO Oct 29, 2024; on Category 2; WADA classification ambiguous. No state-level peptide restrictions beyond federal law in New York.
category: no approval · last verified May 13, 2026
§ 01
Quick answer
Endogenous neuropeptide in Imperial College London Phase 1/2 trials; PCAC voted NO Oct 29, 2024; on Category 2; WADA classification ambiguous. No state-level peptide restrictions beyond federal law in New York.
§ 02
Full status breakdown
Federal status
FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: PCAC-rejected; FDCA applies for human-use sale.
Personal possession: Not federally criminalized.
New York — state-specific
Sport-body status
WADA 2026
not on prohibited list
Not explicitly named on 2026 list. WADA classification is genuinely ambiguous — kisspeptin stimulates LH/FSH via GnRH, could be captured under S4 (Agents Affecting Endogenous Hormones) or S2 (peptide hormones).
USADA
unknown
NCAA
unknown
What we couldn’t verify
§ 03
Also known as
Kisspeptin-10 is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
KP-10Kp10metastin 45-54endogenous neuropeptide kisspeptin
§ 04
Disclaimer
§ 05
Related
- Back to peptide legality lookup — pick a different compound or state
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch